Ajinomoto North America, Inc., a wholly owned subsidiary of Ajinomoto Co., Inc., now offers to North American customers’ pharmaceutical-grade L-cystine that is produced using fermentation technology.
Ajinomoto’s L-cystine is manufactured at the company’s amino acid manufacturing facility in Kawasaki, Japan under strict cGMP guidelines using a patented fermentation process. It is produced from non-animal raw materials, kosher and halal certified and European Pharmacopoeia compliant. Fermented L-cystine is the latest addition to Ajinomoto’s full line of amino acids and amino acid derivatives.
Fermentation is a microbial process whereby natural renewable substrates are converted to finished products, such as amino acids. Ajinomoto’s fermentation manufacturing process, which uses plant-based raw materials, offers significant advantages compared to other traditional manufacturing processes of Cystine and its derivatives, which may use human or animal materials – including human hair and bird feathers. Additionally, manufacturing by fermentation is sustainable and minimizes environmental impact by producing less waste and by-products.
The global market for Amino Acids is projected to grow year over year through 2020, driven by an increasing awareness of the role of amino acids in physiology, an aging population, interest in sports nutrition and the continual identification of human and animal disorders caused by amino acid deficiencies. Ajinomoto North America continues to evolve to meet the growing demand for high quality amino acids in the global market and here in North America.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.